Haley Laken, Ph.D. is a drug development strategy expert encompassing target identification through product approval. She is currently CSO at Zenas Biopharma (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases.

Prior to joining Zenas, Dr. Laken served as Chief Operating Officer at Tabby Therapeutics, a privately held biotech company focused on B-cell engineering where she led all scientific initiatives and company operations. Previously, Dr. Laken held roles of increasing responsibility at Jounce Therapeutics, culminating as Chief Development Officer and a member of the executive team. Prior to that, she served in a senior program leadership role at TESARO, where she led multiple biologic development programs from research through early clinical development. Dr. Laken also held strategic drug development leadership roles at Rhythm Pharmaceuticals, Pfizer and Wyeth. Dr. Laken earned a B.A. in Biology from DePauw University and a Ph.D. in Human Genetics and Molecular Biology from Johns Hopkins University, and she is currently a member of the Board of Directors at InCephalo Therapeutics.

Dr. Laken received her Ph.D. in human genetics and molecular biology from Johns Hopkins University and a B.A. in biology from DePauw University.